Q1 data analysis
It is no understatement to claim that 2018 has kicked off with a bang, setting the stage for what could become one of the most successful years for university venturing. The jaw-dropping $8.7bn acquisition of Ohio State University’s gene therapy developer Avexis by Novartis may be fresh on everyone’s mind, but it happened earlier this month so will not register in the graphs below. Yet the figures for the first quarter are impressive.
When Global University Venturing undertook its annual…
